Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-08-27 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于举行2023年半年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 half-year performance online briefing (业绩网上说明会) by the company. It invites investors to participate and submit questions in advance. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming event related to the interim results. The document length is short (668 characters) and it is clearly an announcement rather than the report itself. Therefore, it fits best under the category of Investor Presentation (IP), as it is a detailed presentation event focusing on financial results and investor communication, not the report itself or a simple announcement of report publication.
2023-08-27 Chinese
独立董事关于第二届董事会第十三次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing their independent opinion on matters reviewed at the company's board meeting, specifically regarding a special report on the use of raised funds for the first half of 2023. It is not the report itself but an opinion or certification related to the report. The document is short (470 characters) and does not contain substantive financial data or the full report. It is essentially an attestation or certification by independent directors. According to the rules, such documents should be classified as Regulatory Filings (RNS) rather than the report itself or other categories.
2023-08-27 Chinese
2023年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2023, including balances, amounts, and related accounting subjects. It includes signatures of accounting and company responsible persons, indicating it is a formal financial disclosure. The content is specific to a half-year period and contains substantive financial data, not just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR), which covers comprehensive financial data for a period shorter than a full fiscal year. H1 2023
2023-08-27 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "恩威医药股份有限公司 2023 年半年度报告全文" which translates to "Enwei Pharmaceutical Co., Ltd. 2023 Semi-Annual Report Full Text." It includes detailed financial data, management discussion and analysis, company overview, business segments, financial indicators, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2023 to June 30, 2023, confirming it covers a half-year period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the company's second board of directors. It includes details about the meeting date, attendance, and voting results on specific agenda items such as approval of the 2023 semi-annual report and a special report on the use of raised funds. The document does not contain the full semi-annual report itself but references where the full report can be found. It is a board meeting resolution announcement rather than the report or financial statements. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is an announcement of decisions made by the board, not the report itself.
2023-08-27 Chinese
2023年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况的专项报告（2023年半年度）" which translates to a "Special Report on the Annual Deposit and Use of Raised Funds (2023 Half-Year)". It details the amount of funds raised, their deposit, usage, interest income, and management according to regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and provides detailed financial data on the use of raised capital for the half-year period ending June 30, 2023. The document length is 3763 characters, which is relatively short but contains substantive financial data and analysis on the use of capital raised, not just an announcement or certification. This fits the category of a Capital/Financing Update (CAP) as it focuses on fundraising proceeds and their management and usage rather than a full annual or interim report or other categories.
2023-08-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.